Tumor ki67 Impact on Survival in Male Breast Cancer Patients: A Systematic Review and Meta-Analysis.

IF 2.9 3区医学 Q2 ONCOLOGY

Clinical breast cancer Pub Date : 2025-05-22 DOI:10.1016/j.clbc.2025.05.013

Stephen Kinsey-Trotman, Alain Nguyen, Suzanne Edwards, Adam Swalling, Pallave Dasari, David Walsh, Wendy V Ingman

{"title":"Tumor ki67 Impact on Survival in Male Breast Cancer Patients: A Systematic Review and Meta-Analysis.","authors":"Stephen Kinsey-Trotman, Alain Nguyen, Suzanne Edwards, Adam Swalling, Pallave Dasari, David Walsh, Wendy V Ingman","doi":"10.1016/j.clbc.2025.05.013","DOIUrl":null,"url":null,"abstract":"Purpose: Histological features with prognostic utility for survival in male breast cancer remain elusive. Tumor ki67 expression may provide an early prognostic marker in this disease. This systematic review investigated ki67 prognostication for overall survival in male breast cancer patients.Methods: Following prospective registration MEDLINE, PUBMED Central and EMBASE databases were searched to identify suitable studies. Studies were considered for meta-analysis when both comparable research methodologies were utilized and survival outcomes were reported for the same threshold value for ki67.Results: A total of fifteen observational type studies were included in the review with 9 meeting inclusion criteria for data extraction. Six studies contributed to a meta-analysis. Two studies demonstrated a statistically-significant difference in survival outcome at a ki67 threshold of 20%, however meta-analysis for ki67 set at 2 thresholds (14% and 20%) did not demonstrate any significant association with overall survival.Conclusions: This review did not confirm an association between ki67 and overall survival in male breast cancer patients. Further research including the use of artificial intelligence methods and consideration of a higher threshold value are needed to better define Tumor ki67 in this patient group.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.05.013","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Histological features with prognostic utility for survival in male breast cancer remain elusive. Tumor ki67 expression may provide an early prognostic marker in this disease. This systematic review investigated ki67 prognostication for overall survival in male breast cancer patients.

Methods: Following prospective registration MEDLINE, PUBMED Central and EMBASE databases were searched to identify suitable studies. Studies were considered for meta-analysis when both comparable research methodologies were utilized and survival outcomes were reported for the same threshold value for ki67.

Results: A total of fifteen observational type studies were included in the review with 9 meeting inclusion criteria for data extraction. Six studies contributed to a meta-analysis. Two studies demonstrated a statistically-significant difference in survival outcome at a ki67 threshold of 20%, however meta-analysis for ki67 set at 2 thresholds (14% and 20%) did not demonstrate any significant association with overall survival.

Conclusions: This review did not confirm an association between ki67 and overall survival in male breast cancer patients. Further research including the use of artificial intelligence methods and consideration of a higher threshold value are needed to better define Tumor ki67 in this patient group.

查看原文本刊更多论文

肿瘤ki67对男性乳腺癌患者生存的影响：系统回顾和荟萃分析

目的：男性乳腺癌的组织学特征与预后的关系尚不明确。肿瘤中ki67的表达可能是该疾病的早期预后指标。本系统综述调查了ki67对男性乳腺癌患者总生存率的预测。方法：通过前瞻性注册，检索MEDLINE、PUBMED Central和EMBASE数据库以确定合适的研究。当使用了两种可比较的研究方法，并报告了相同ki67阈值的生存结果时，研究被考虑进行荟萃分析。结果：本综述共纳入15项观察型研究，其中9项符合资料提取的纳入标准。六项研究促成了一项荟萃分析。两项研究表明，ki67阈值为20%时，生存结果有统计学意义上的差异，然而，ki67阈值为14%和20%时的荟萃分析未显示与总生存有任何显著关联。结论：本综述未证实ki67与男性乳腺癌患者总生存率之间的关联。需要进一步的研究，包括使用人工智能方法和考虑更高的阈值来更好地定义该患者组的肿瘤ki67。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical breast cancer 医学-肿瘤学

CiteScore

5.40

自引率

3.20%

发文量

174

审稿时长

48 days

期刊介绍： Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.